Who has invested in Phagenesis?

EQT Life Sciences, Sectoral Asset Management are named among the investors backing Phagenesis.

Phagenesis Funding: $70M Raised, Series D (2024)

Phagenesis funding overview

Phagenesis has raised $70M in total disclosed funding. That places its disclosed total in the $25M–$100M range. Its most recent disclosed round is a Series D announced in February 2024. The round record for Phagenesis runs through 2024; nothing later has been disclosed. Investors on record include EQT Life Sciences, Sectoral Asset Management. 2 distinct backers are named across the disclosed rounds.

Phagenesis at a glance

Total raised: $70M
Latest round: Series D
Latest round date: February 2024
Notable investors: EQT Life Sciences, Sectoral Asset Management

Frequently asked about Phagenesis funding

How much has Phagenesis raised?: Phagenesis has raised $70M in total disclosed funding across the rounds on record.
Who has invested in Phagenesis?: EQT Life Sciences, Sectoral Asset Management are named among the investors backing Phagenesis.
What was the latest Phagenesis funding round?: The most recent disclosed round is a Series D, announced in February 2024.
Where is Phagenesis based?: No headquarters location is disclosed for Phagenesis.
When did Phagenesis last raise?: The last disclosed Phagenesis round closed in February 2024 at Series D.

Round data for Phagenesis is compiled from public filings and announcements; blank fields mean nothing has been disclosed rather than nothing exists. Continue with the companies and backer lists below.

Phagenesis Funding: $70M Raised, Series D (2024)

Phagenesis funding overview

Phagenesis at a glance

Frequently asked about Phagenesis funding

Companies related to Phagenesis (18)

Browse related funding lists (5)